AFMD Affimed NV

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

 

FORM 6-K

__________________

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

For the month of June, 2018

 

Commission File Number: 001-36619

 

__________________________________

 

Affimed N.V.

__________________________________

 

Im Neuenheimer Feld 582,

69120 Heidelberg,

Germany

(Address of principal executive offices)

__________________________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x       Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

AFFIMED N.V.

 

On June 15, 2018, Affimed N.V. presented updated data in respect of AFM13 in combination with Keytruda ® (Pembrolizumab) in patients with relapsed/refractory Hodgkin Lymphoma at EHA.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Heidelberg, Germany, June 15, 2018.

 

	AFFIMED N.V.
	By:	/s/ Adi Hoess
		Name:	Adi Hoess
		Title:	Chief Executive Officer
	By:	/s/ Florian Fischer
		Name:	Florian Fischer
		Title:	Chief Financial Officer

 

 

EXHIBIT INDEX

 

Exhibit	Description of Exhibit
99	Press Release dated June 15, 2018